N/A
N/A
N/A
N/A
N/A
Not Enrolling
Both
Carcinoma
Both
Carcinoma
Trial Information
Inclusion Criteria:
- Indication for Irinotecan according to the SmPC and treating physician
Exclusion Criteria:
- according to the Irinotecan SmPC
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
The Quantity of Irinotecan onkovis needed per treatment cycle
Outcome Description:
Determine the quantity of Irinotecan onkovis needed pro treatment cycle
Outcome Time Frame:
up to 24 weeks
Safety Issue:
No
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
ONKOIRI01
NCT ID:
NCT01840280
Start Date:
May 2013
Completion Date:
Related Keywords:
- Carcinoma
- carcinoma
- colorectal cancer
- ambulant chemotherapy
- treatment cycles
- Irinotecan
- Irinotecan onkovis
- Quantity of Irinotecan
- Packaging Sizes
- Carcinoma
Name | Location |
|---|
